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BACKGROUND: This study aimed to define the maximally tolerated dose (MTD) of sunitinib combined with two different infusion
schedules of ifosfamide.
METHODS: Patients with advanced solid tumours, good performance score, good organ function, and no standard therapy available
were eligible. Continuous once daily sunitinib, in escalating doses per cohort, was combined with ifosfamide, 9gm
 2 for 3 days or
6gm
 2 for 5 days, administered every 3 weeks. Pharmacokinetic (PK) and pharmacodynamic (PD) assessments were performed.
RESULTS: With growth-factor support, the MTD of sunitinib combined with either ifosfamide schedule was 12.5mg in 32 patients
enrolled. Neutropenia-related adverse events were dose-limiting toxicities. Sunitinib did not affect ifosfamide PK. Ifosfamide
significantly decreased exposure to sunitinib and increased exposure to its metabolite, SU12662. No consistent changes in PD
parameters were observed.
CONCLUSION: With growth-factor support, the MTD of sunitinib with both ifosfamide schedules was 12.5mg. Ifosfamide produced
decreased sunitinib blood levels because of CYP3A induction. As PK interactions cannot explain the relatively low sunitinib doses that can
be combined with ifosfamide, synergy in toxicity is likely. Whether this also holds true for anti-tumour activity needs to be further explored.
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The introduction of tyrosine kinase inhibitors (TKIs) specifically
inhibiting tumour-driving factors was accompanied with high
expectations with regard to their activity against solid malignancies.
Their single-agent activity in most tumour types is, however, modest,
with obvious exceptions in tumours such as renal cell carcinoma
(RCC) and gastrointestinal stromal tumours (GIST) (Verweij et al,
2004; Motzer et al, 2007).
One potential way to augment the activity of TKIs is to combine
them with conventional cytotoxic agents. In particular, combina-
tions of TKIs targeting the vascular endothelial growth factor
(VEGF) pathway and conventional cytotoxic agents seem
attractive, given several potential mechanisms that may yield
synergistic anti-tumour effects. Vascular endothelial growth factor
produced by tumour cells results in the formation of new
vasculature that is abnormal in structure and more permeable
than normal vasculature. This causes a high interstitial pressure
within the tumour, hindering the penetration of drugs into
tumours (Boucher and Jain, 1992). Inhibition of VEGF-mediated
effects has been shown to decrease intra-tumoural interstitial
pressure, thereby enhancing the delivery of concomitantly
administered drugs (Boucher and Jain, 1992; Heldin et al, 2004;
Willett et al, 2004). Other mechanisms that may contribute to
synergistic interaction between VEGF-pathway inhibitors and
conventional cytotoxic drugs include prevention of endothelial
progenitor cell mobilisation from the bone marrow induced by
chemotherapy and decreased production of tumour factors
conferring resistance against chemotherapy (Simakajornboon
et al, 2001; Dias et al, 2002; Tran et al, 2002; Riedel et al, 2004;
Shaked et al, 2008).
Sunitinib is a potent inhibitor of VEGF receptors (VEGFR)1–3,
KIT, platelet-derived growth factor receptor-a and-b, and Fms-like
tyrosine kinase-3 (Flt3), and is one of the first and most commonly
used VEGFR-TKIs. It is currently registered for the treatment of
advanced RCC and imatinib-refractory GIST (Demetri et al, 2006;
Motzer et al, 2007) and is being explored for its anti-tumour
activity in a wide range of other tumour types. A potential
attractive agent to combine with sunitinib is ifosfamide, an
alkylating agent with established activity against a similar wide
range of tumour entities including breast cancer, testicular cancer,
lung cancer, sarcomas, and central nervous system (CNS) tumours
such as medulloblastomas.
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sThis study aimed to define the maximally tolerated dose (MTD) of
ifosfamide combined with sunitinib. Two different infusion schedules
of ifosfamide were explored. In addition, extensive pharmacokinetic
(PK) and pharmacodynamic (PD) studies were conducted.
PATIENTS AND METHODS
Patient selection
Patients with histologically or cytologically confirmed advanced or
metastatic solid tumours, for whom no standard therapy was available,
with an Eastern Cooperative Oncology Group (ECOG) performance
status o2, were eligible. Other inclusion criteria were evaluable or
measurable disease according to RECIST version 1 (Therasse et al,
2000), age X18 years, life expectancy X12 weeks, adequate bone
marrow (neutrophil count X1.5 10
9 cells per l; platelets X100 10
9
cells per l; and haemoglobin X6.0mmoll
 1), liver (serum bilirubin
p1.5  upper limit of normal (ULN) and serum ASAT and ALAT
p2.5  ULN or, if liver metastases were present, p5  ULN), and
renal function (serum creatinin p1.5  ULN and creatinine clearance
X60mlmin
 1), two functioning kidneys, systolic blood pressure
o150mmHg, and diastolic blood pressure o90mmHg (treatment
with two anti-hypertensive drugs was allowed). Main exclusion criteria
were history of cardiovascular disease, known HIV seropositivity, and
signs or symptoms of CNS metastases.
The study was designed and conducted under the approval of
appropriate institutional review boards (METC 2006–273 and
CME 06–273) and in accordance with the principles embodied in
the Declaration of Helsinki. Written informed consent was
obtained from each participant.
Study design and drug dosing, escalation, and
administration
Daily oral sunitinib was planned to be evaluated in three dose
cohorts, 12.5mg, 25mg, and 37.5mg, in combination with a fixed
dose of ifosfamide, according to one of the standard schedules of
monotherapy ifosfamide: 9gm
 2 administered as 3-day continuous
intravenous infusion (CIV) at 3-weekly intervals. After establishing
the MTD of sunitinib with this dose and schedule of ifosfamide, this
sunitinib dose was evaluated with ifosfamide at 6gm
 2 given as
5-day CIV. The latter ifosfamide schedule was chosen as in multidrug
cytotoxic schedules; ifosfamide is frequently administered for 5 days,
for example, in combination with cisplatin and etoposide. Additional
patients were treated at the MTD of sunitinib with both ifosfamide
regimens to get a better insight into the safety profile of the
combination and to study PK drug–drug interactions. With regard to
the latter, patients enrolled in these dose-expansion cohorts initiated
sunitinib at day 8 of the first cycle instead of at day 1, which enables
the investigation of the PK of sunitinib alone. On the basis of the
mean half-life of sunitinib (40–60h), it was anticipated that steady
state of sunitinib levels was reached before initiating the second cycle
of ifosfamide. Samples for PK evaluation were collected during
the first two treatment cycles. After a protocol amendment because
of prolonged neutropenia, granulocyte-colony stimulating factor
(pegfilgrastim 6mg once per cycle) was administered to all patients.
Twelve days before the first administration of study treatment
and throughout the whole study, concurrent treatment with known
CYP3A4 inhibitors or inducers was not allowed.
Using the Common Terminology Criteria for adverse events
(CTCAE), version 3.0, dose-limiting toxicity (DLT) was defined as
the following toxicity during the first treatment cycle: grade 4
neutropenia X7 days, febrile neutropenia, grade 4 thrombocyto-
penia, serum creatinine X2  ULN, and any drug-related grade 3
or 4 non-haematological toxicity excluding the following
events: nausea and vomiting without optimal supportive care,
grade 3 fatigue o7 days, and hypertension not refractory to
anti-hypertensive medication. If patients developed a systolic blood
pressure 4160mmHg, a diastolic blood pressure 4100mmHg, or
an increase in diastolic blood pressure 420mmHg, which
(despite anti-hypertensive medication with an ACE inhibitor and a
calcium-channel blocker) was not adequately controlled within
2 weeks, treatment with sunitinib was stopped. In case of grade
4 hypertension, sunitinib was also discontinued. A dose delay or
interruption for longer than 2 weeks was also classified as DLT.
A classic 3þ3 design was applied, implying that if a DLT was
observed in one patient, three additional patients were recruited at
that dose level, with the dose level escalating if no further DLT
occurred at that level. If a DLT was observed in X2 patients in a
cohort, it could be concluded that the MTD had been exceeded.
Maximally tolerated dose was defined as the highest dose level with
a DLT incidence of o33%.
Before commencing each ifosfamide cycle, patients had to have
neutrophils X1.5 10
9 cells per l and platelets X100 10
9 cells
per l. If a patient experienced an ifosfamide-related DLT, the dose
of ifosfamide was reduced by 25%. A dose reduction of more than
50% of the initial ifosfamide dose was not allowed. In those
patients experiencing a DLT related to sunitinib, sunitinib was
withheld for a maximum of 2 weeks. If toxicity resolved to grade 0
or 1, continuation at the next lower dose cohort level was allowed
for the subsequent courses. Patients were treated for a maximum
of six ifosfamide cycles. Those patients who experienced a benefit
from the combination of sunitinib and ifosfamide were allowed to
continue treatment with sunitinib monotherapy. Treatment was
continued until disease progression or unacceptable toxicity.
PK sampling and analysis
In patients enrolled in the expansion cohorts, blood samples for
PK analysis were collected.
For ifosfamide and its most important metabolites, 2-dechloro-
ethyl-ifosfamide, 3-dechloroethyl-ifosfamide, and 4-hydroxy-ifos-
famide blood samples were collected in the presence of lithium
heparin as anti-coagulant before infusion and 3, 6, 10, and 24h
after the start of ifosfamide infusion, and thereafter every 12h until
the end of infusion, before the end of infusion and 1, 3, 6, 12, and
24h after the end of infusion during the first two treatment cycles.
Blood samples were centrifuged within 15min after collection for
10min at 3000g at 41C. Subsequently, an aliquot of exactly 1ml of
the plasma supernatant was transferred into a vial containing
100ml of a 2M semicarbazide solution and was stored at o 701C
until analysis of 4-hydroxy-ifosfamide. The remaining plasma was
stored at o 701C, without any additive, until the simultaneous
analysis of ifosfamide and its 2-dechloroethyl and 3-dechloroethyl
metabolites. Ifosfamide and the 2-dechloroethyl and 3-dechloro-
ethyl metabolites were simultaneously quantitated by a vali-
dated liquid chromatography tandem triple quadrupole mass
spectrometry (LC-MS/MS) assay. Analytes were extracted by
liquid–liquid extraction from 10ml aliquots of plasma with
cyclofosfamide as internal standard. For 4-hydroxy-ifosfamide, a
separate LC-MS/MS method was developed and validated. Aliquots
of 50ml of semicarbazide-stabilised plasma were extracted by
liquid–liquid extraction with the same internal standard. Peak
area ratios were a function of the concentration from 50.0 to
5000ngml
 1 for all analytes, with the within and between-run
precisions p4.9 and p5.2%, respectively, and the average
accuracy ranging from 90.0 to 105.4%. Individual PK parameters
for ifosfamide, 2-dechloroethyl-ifosfamide and 3-dechloroethyl-
ifosfamide, and 4-hydroxy-ifosfamide were estimated using non-
compartmental analysis (1/y weighting factor) using the software
programme WinNonLin 5.0 (Pharsight, Mountain View, CA, USA).
For the analysis of sunitinib and its active metabolite SU12662,
blood samples were taken before dosing every 3–4 days and every
day during the second ifosfamide cycle. Blood samples were
centrifuged within 15min after collection for 10min at 3000g
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sat 41C. The plasma was stored at o 701C, in tubes wrapped with
aluminium foil, until the simultaneous analysis of sunitinib and
SU12662, as recently published (De Bruijn et al, 2010).
Statistical data analysis
Statistical analysis, using software package SPSS (version 15
(Softonic International, San Francisco, CA, USA)), of the changes
in sunitinib concentration was carried out by Wilcoxon signed
ranks test using the pre-ifosfamide sunitinib concentration as
comparator. Changes in ifosfamide concentration have been
evaluated using the same test. Correlation of the auto-induction
rate of ifosfamide and changes in sunitinib concentrations was
carried out by the Pearson’s correlation test.
Biomarker analysis
Circulating endothelial cell (CEC) enumeration, considered to
reflect vascular damage, was determined using the CellSearch
system (Veridex, LCC, Raritan, NJ, USA) (Rowand et al, 2007).
Plasma concentrations of VEGF and soluble VEGFR2 (sVEGFR2)
were determined using ELISA (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s instructions.
RESULTS
Dose escalation, MTD, and dose intensity
In total, 32 patients were enrolled (Table 1). At the first dose level
(sunitinib 12.5mg and ifosfamide 9gm
 2 for 3 days), a DLT
occurred in two out of six patients; both experienced a prolonged,
uncomplicated neutropenia (47 days). This was pre-specified as
exceeding the MTD. The protocol was amended and subsequent
patients were treated with pegfilgrastim. The first dose level was
repeated and no DLTs were observed. However, in the subsequent
25mg sunitinib cohort, three DLTs occurred in five patients
(two grade 4 febrile neutropenia; in one patient, hypertension
accompanied by chest pain), indicating that the MTD was exceeded,
rendering 12.5mg sunitinib plus ifosfamide 9gm
 2 for 3 days
combined with pegfilgrastim to be the MTD. After confirming the
tolerability at this dose level (in total, one DLT in nine patients: grade
3 febrile neutropenia), the safety of this sunitinib dose was tested
with the second ifosfamide regimen (6gm
 2 for 5 days), also
supported with pegfilgrastim. In nine patients, one DLT was
observed (grade 3 ifosfamide-induced encephalopathy).
The dose intensities of sunitinib at the MTD were 93 and 98%
during combination treatment with the 3-day and 5-day schedule,
respectively. A median of 4 and 3.5 cycles of ifosfamide was
administered, resulting in an ifosfamide dose intensity of 93 and
96% for the 3-day and 5-day schedule, respectively.
Toxicity
The non-haematological toxicity of sunitinib and ifosfamide was
mainly grade 1–2 toxicity. Haematological toxicity was more
pronounced, as grade 3–4 neutropenia was observed in 19 patients
(59%), resulting in one or more episodes of febrile neutropenia in 7
patients (22%) (Table 2). At the MTD, in almost every patient in the
3-day schedule (eight out of nine; 89%), grade 3–4 neutropenia, and
in four patients febrile neutropenia, occurred during combination
therapy, whereas only three out nine (33%) patients treated with the
5-day schedule had grade 3–4 neutropenia, and no episodes of
febrile neutropenia were observed.
Pharmacokinetics
Pharmacokinetic data of sunitinib and ifosfamide were obtained in
six patients per ifosfamide schedule at the MTD. Plasma concen-
tration time curves of ifosfamide, 2-dechloroethyl-ifosfamide,
Table 1 Demographics and baseline characteristics (in numbers (%) if
not otherwise specified)
Age (median, years) 53 (range 29–74)
Gender
Male 16 (50)
Female 16 (50)
WHO performance status
0 11 (34)
1 21 (66)
Tumour type
Sarcoma 15 (47)
Chondrosarcoma 2 (6)
Leiomyosarcoma 2 (6)
Liposarcoma 2 (6)
Ewing sarcoma 2 (6)
Pleomorphic sarcoma 2 (6)
Other sarcoma types 5 (16)
Carcinoma of unknown primary tumour 3 (9)
Neuroendocrine carcinoma 2 (6)
Non-small-cell lung cancer 2 (6)
Melanoma (uveal and mucosal) 2 (6)
Miscellaneous
a 8 (26)
Previous non-hormonal systemic anticancer treatment
0 5 (16)
1 18 (56)
2 5 (16)
3 2 (6)
4 2 (6)
Abbreviation: WHO¼World Health Organisation.
aBile duct carcinoma, breast
cancer, adenoid cystic carcinoma, endometrial cancer, urothelial cancer, pancreatic
cancer, chordoma and cervical carcinoma; for all the cases n¼1.
Table 2 Adverse events during combination therapy of sunitinib and
ifosfamide (number of patients (%))
First cycle adverse
events
Adverse events at all
combination cycles
All
grades Grade 3/4 All grades Grade 3/4
Haematological toxicity
Anaemia 28 0 31 2
Thrombocytopenia 19 4 22 9
Neutropenia 14 10 21 19
Febrile neutropenia 3 3 7 7
Non-haematological toxicity
Fatigue 24 2 29 4
Nausea 20 0 24 0
Constipation 20 0 24 0
ALAT and/or ASAT 20 0 21 0
Alopecia 19 0 26 0
Vomiting 14 0 19 0
Creatinine/renal 9 0 12 1
Hypo-/hyperkalaemia 5/1 1/0 5/1 2/0
Bilirubin 5 0 6 0
Diarrhoea 4 0 5 0
Pyrosis 3 0 5 0
TSH increase/decrease 2/2 0 2/2 0
Neurotoxicity 2 1 8 1
Anorexia 2 0 11 1
Haemorrhage 1 1 1 1
Abbreviations: ALAT¼alanine transaminase; ASAT¼aspartate aminotransferase;
TSH¼thyroid-stimulating hormone.
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s3-dechloroethyl-ifosfamide, and 4-hydroy-ifosfamide were not
affected by sunitinib (Figure 1). Ifosfamide concentrations were
significantly lower at 48h (C48h) compared with 24h (C24h) in the
3-day and 5-day schedule (40% and 17%, respectively; both
P¼0.028), in line with the known ifosfamide capacity to induce its
own CYP3A-mediated metabolism (Boddy et al, 1995).
Sunitinib trough concentrations decreased during ifosfamide
infusions during the 3-day and 5-day schedule (Figure 2 upper
graphs). As presented in Figure 3 (upper panel), trough concentra-
tions were significantly lower at 1, 2, and 3 days (Po0.05) after the
start of ifosfamide infusion in the 3-day schedule, whereas during the
5-day schedule, the decrease was less pronounced, not reaching
statistical significance. The decrease in sunitinib was paralleled by
an increase in the trough concentrations of its pharmacologically
active metabolite SU12662 (Figure 2, lower graphs), which reached
statistical significance in both the 3-day and 5-day ifosfamide
schedules (Figure 3, middle panel). However, the sum of sunitinib
and its pharmacologically active metabolite, SU12662, slightly
decreased during the ifosfamide infusions, reaching significance
only 1 day after the start of ifosfamide infusion in the 3-day schedule
(Po0.05) (Figure 3, lower panel).
The auto-induction rate of ifosfamide, expressed as C48h/C24h,
was correlated to the decrease in sunitinib trough concentrations,
expressed as Cday2/Cday0 (R
2¼0.47; P¼0.019) (Figure 4).
Biomarker analysis
Circulating endothelial cell enumeration and determination of
plasma concentrations of VEGF and sVEGFR2 with serial sampling
were successful in 22 patients. A wide range in relative changes in
the number of CECs from baseline to post-cycle 2 (0.05–35.2) and
post-cycle 5 (0.09–5.2) was observed. Relative changes from
baseline to post-cycle 2 and post-cycle 5 were widespread for VEGF
(0.04–14.1 and 0.25–5.6, respectively) and less outspoken for
sVEGFR2 (0.63–1.4 and 0.46–1.1, respectively). No consistent
change in time, correlation with dose levels, with the occurrence of
febrile neutropenia, or tumour response was observed for VEGF or
sVEGFR2 plasma concentrations or number of CECs.
Anti-tumour activity
All 32 patients were assessable for efficacy. Partial responses were
seen during the 3-day schedule in three patients (one patient with
adenocarcinoma of unknown primary, one patient with a sarcoma
NOS, and one patient with a liposarcoma). Disease stabilisation
was observed in 17 patients in whom a prolonged (43 months)
disease stabilisation was observed in 9 patients (7 out of 23
patients during the 3-day schedule and 2 out of 9 patients during
the 5-day schedule). The latter group consisted of patients with
uveal melanoma, chordoma, chondrosarcoma, Ewing sarcoma,
uterus sarcoma, endometrial carcinoma, small-cell neuroendocrine
carcinoma, non-small-cell lung cancer, and carcinoma of unknown
primary (all entities n¼1).
DISCUSSION
This is one of the first full reports on a combination of sunitinib
with a conventional cytotoxic agent and the first on the
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scombination of ifosfamide with a VEGFR-inhibiting TKI.
Combined with ifosfamide at 9gm
 2 given continuously over 3
days, it seemed that the MTD of sunitinib is mainly determined by
neutropenia-related events. With growth factor support, sunitinib
at the lowest evaluated dose of 12.5mg daily was feasible in
combination with ifosfamide at 9gm
 2 for 3 days and at 6gm
 2
for 5 days. Importantly, our data on the occurrence of
neutropenia-related adverse events should be appreciated in the
context of toxicity from ifosfamide monotherapy. Ifosfamide
given at 9gm
 2 for 3 days, as an established treatment schedule,
has an observed incidence in a phase III trial of 62.7% grade
3–4 neutropenia when given as first-line therapy. In addition,
during a mean number 3.7 cycles of therapy, 19.6% of the
patients encountered febrile neutropenia (Lorigan et al, 2007).
Furthermore, sunitinib administered as a single agent produces
grade 3–4 neutropenia in 12% of patients (Motzer et al, 2007).
Given these figures, it comes as no surprise that neutropenia-
related adverse events were the determining toxicity for the MTD
of the combination. On the basis of the findings in this study, it is
clear that the occurrence of neutropenia-related events is not
attributable to changes in drug exposure.
Recently, several trials on sunitinib combined with conventional
cytotoxic agents have been reported, although only in abstract
form. The majority of the tested combinations also yielded a high
incidence of neutropenia-related events, which were frequently
dose-limiting toxicities. This held true for the combinations of
sunitinib with docetaxel, irinotecan, FOLFIRI, carboplatin/
paclitaxel, or gemcitabine/cisplatin, preventing sunitinib from
being administered at full single-agent doses (Reck et al, 2007;
Robert et al, 2007; Boven et al, 2008; Mariani et al, 2008; Starling
et al, 2008; Cardoso et al, 2009; Friedman et al, 2009; Heath et al,
2009; Zurita et al, 2009). The only two combinations not hampered
by neutropenia-related adverse events were sunitinib with
capecitabine or with gemcitabine (Michaelson et al, 2008; Royce
et al, 2008).
What becomes apparent from these studies is the fact that the
schedule in which sunitinib is administered is likely to largely
impact the tolerability of combinations in terms of neutropenia-
related events. The recommended dose of sunitinib as a single
agent was initially reported as 50mg administered daily for 28 days
every 6 weeks. However, we choose to administer sunitinib
continuously. Evidence accumulates that persistent inhibition of
the VEGF pathway might be advantageous over intermittent
dosing, although both dosing schedules have not been directly
compared yet. For combinations, however, toxicity might be more
pronounced using sunitinib continuously rather than intermit-
tently, as recovery from toxicity induced by the cytotoxic agent
might be hampered in the presence of sunitinib. Accordingly,
preliminary data on the combination of sunitinib with FOLFIRI
suggest that continuous dosing of sunitinib was not feasible
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sbecause of neutropenia, whereas in contrast, sunitinib
administered in a 4-week on, 2-week off schedule could be applied
at a dose of 37.5mg in combination with FOLFIRI (Starling et al,
2008). From a mechanism of action point of view, the least-
desirable administration schedule of sunitinib might be best
combinable with chemotherapy. In contrast, sunitinib continu-
ously administered, as well as administered in the 4-week on
2-week off schedule in combination with capecitabine, was
tolerated at the same sunitinib dose (37.5mg per day); however,
as mentioned before, neutropenia was not a major issue in that
specific combination (Royce et al, 2008).
Besides the neutropenia-related adverse events, the combination
of (a relatively low dose of) sunitinib, using continuous admin-
istration, and ifosfamide was well tolerated (Table 2).
Assessing the PK of both drugs, a clear influence of ifosfamide
on the PK of sunitinib was observed. This interaction resulted in
a decreased systemic exposure to sunitinib and an increased
exposure to its active metabolite, SU12662. Although the exact
contribution of the active metabolite SU12662 to the toxicity and
efficacy pattern of sunitinib in humans is unknown, preclinical
data point towards equipotent inhibitory capacities (Baratte et al,
2004). Ifosfamide is a potent inhibitor of CYP3A, the enzyme
mainly responsible for conversion of sunitinib into SU12662
(Faivre et al, 2006). This observed drug–drug interaction is in line
with findings in healthy subjects showing a decreased systemic
exposure to sunitinib when concomitantly treated with the potent
CYP3A inducer rifampicin (Bello et al, 2005) and an increased
exposure in the presence of ketoconazole, a potent CYP3A
inhibitor (Washington et al, 2003). Pharmacokinetic drug–drug
interactions have been studied combining sunitinib with
gemcitabine, capecitabine, paclitaxel, and docetaxel with or
without trastuzumab, but no relevant PK interactions were
observed in these studies (Mariani et al, 2008; Michaelson et al,
2008; Royce et al, 2008; Cardoso et al, 2009).
As a relatively low dose of sunitinib in combination with a
standard dose of ifosfamide already results in DLT, which cannot
be explained by PK interactions, synergy in toxicity seems most
likely. An explanatory hypothesis for the occurrence of the
described neutropenia-related events while combining ifosfamide
with sunitinib might consist of a dual hit. Initially, neutrophils
decrease because of the administration of ifosfamide. The
physiological response of mobilisation and proliferation of
haematopoietic progenitor cells to restore the neutrophil count is
hampered because of inhibition by sunitinib of tyrosine kinases
involved in haematopoietic progenitor cell survival and prolifera-
tion, such as Flt3 and colony-stimulating factor receptor (CSF-1R).
Importantly, a multiple drug combination should not be
discarded as a result of its low combinability because of synergy
in toxicity alone, as this synergistic interaction may also occur at
tumour cell level.
As PD parameters, CEC numbers and plasma concentrations of
VEGF and sVEGFR2 were assessed. Alterations in CEC numbers is
likely to reflect vascular damage (Strijbos et al, 2008), but no
consistent changes in CEC numbers could be seen, either during
therapy or between the two sunitinib doses explored. In contrast to
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smonotherapy with sunitinib (Deprimo et al, 2007), no consistent
pattern in the changes in plasma concentrations of VEGF and
sVEGFR2 was observed.
In conclusion, the MTD of daily sunitinib combined with
continuously infused ifosfamide (9gm
 2 for 3 days) supported by
pegfilgrastim is 12.5mg. The same dose of sunitinib is feasible
using an ifosfamide schedule of 5 days (total dose per cycle
6gm
 2). Concomitant treatment with ifosfamide significantly
decreased the systemic exposure to sunitinib, whereas the
exposure to its active metabolite, SU12662, increased because of
CYP3A induction. As PK interactions cannot explain the fact that
ifosfamide can be combined safely only with relatively low
sunitinib doses, synergy in toxicity is likely. Whether this holds
true for anti-tumour activity needs to be determined, and it is
particularly attractive to explore this further in tumour types
against which both sunitinib and ifosfamide as monotherapy
exhibit anti-tumour activity, such as soft tissue sarcomas, as well
as lung and breast cancer.
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